JP2012511031A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511031A5
JP2012511031A5 JP2011539777A JP2011539777A JP2012511031A5 JP 2012511031 A5 JP2012511031 A5 JP 2012511031A5 JP 2011539777 A JP2011539777 A JP 2011539777A JP 2011539777 A JP2011539777 A JP 2011539777A JP 2012511031 A5 JP2012511031 A5 JP 2012511031A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539777A
Other languages
Japanese (ja)
Other versions
JP2012511031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067015 external-priority patent/WO2010065961A2/en
Publication of JP2012511031A publication Critical patent/JP2012511031A/ja
Publication of JP2012511031A5 publication Critical patent/JP2012511031A5/ja
Pending legal-status Critical Current

Links

JP2011539777A 2008-12-05 2009-12-07 miR−31に関連する組成物および方法 Pending JP2012511031A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12032208P 2008-12-05 2008-12-05
US61/120,322 2008-12-05
PCT/US2009/067015 WO2010065961A2 (en) 2008-12-05 2009-12-07 Compositions and methods relating to mir-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014167336A Division JP6110346B2 (ja) 2008-12-05 2014-08-20 miR−31に関連する組成物および方法

Publications (2)

Publication Number Publication Date
JP2012511031A JP2012511031A (ja) 2012-05-17
JP2012511031A5 true JP2012511031A5 (cg-RX-API-DMAC7.html) 2012-07-12

Family

ID=42233912

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539777A Pending JP2012511031A (ja) 2008-12-05 2009-12-07 miR−31に関連する組成物および方法
JP2014167336A Expired - Fee Related JP6110346B2 (ja) 2008-12-05 2014-08-20 miR−31に関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014167336A Expired - Fee Related JP6110346B2 (ja) 2008-12-05 2014-08-20 miR−31に関連する組成物および方法

Country Status (6)

Country Link
US (2) US20120041048A1 (cg-RX-API-DMAC7.html)
EP (1) EP2370091B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012511031A (cg-RX-API-DMAC7.html)
AU (1) AU2009322137B2 (cg-RX-API-DMAC7.html)
CA (1) CA2745919A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010065961A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140066671A (ko) * 2011-06-27 2014-06-02 메디뮨 엘엘씨 자가면역 질환에서 사용되는 마이크로rna-31 조성물 및 방법
CN102776191A (zh) * 2012-07-20 2012-11-14 苏州大学 一种微小rna用于调控cd86的基因表达
EP3591050B1 (en) * 2013-09-06 2024-01-31 The University of Tokyo Use of rhoa in cancer diagnosis and inhibitor screening
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
EP3444362B1 (en) * 2014-05-02 2020-12-09 Ruprecht-Karls-Universität Heidelberg Circulating mirnas as early detection marker and prognostic marker
US9623040B2 (en) * 2014-07-14 2017-04-18 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulation by controlling expression levels of microRNAs in dendritic cells
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
WO2018183594A1 (en) * 2017-03-29 2018-10-04 Children's Hospital Medical Center Nucleic acid molecules and their methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
US20050193432A1 (en) 2003-11-18 2005-09-01 Whitehead Institute For Biomedical Research Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2468895B1 (en) * 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
AU2007299748A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2011047147A1 (en) * 2009-10-14 2011-04-21 Baylor College Of Medicine Microrna mirna-31 as a therapeutic approach for the treatment of cancer
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic

Similar Documents

Publication Publication Date Title
BRPI0925311A2 (cg-RX-API-DMAC7.html)
BR112012003062A2 (cg-RX-API-DMAC7.html)
BRPI0924307A2 (cg-RX-API-DMAC7.html)
BR112012000607A2 (cg-RX-API-DMAC7.html)
BR122021004633A2 (cg-RX-API-DMAC7.html)
BR112012000665A2 (cg-RX-API-DMAC7.html)
BR122017024704A2 (cg-RX-API-DMAC7.html)
BR112012009797A2 (cg-RX-API-DMAC7.html)
BRPI0924534A2 (cg-RX-API-DMAC7.html)
BR112012009703A2 (cg-RX-API-DMAC7.html)
BR112012007656A2 (cg-RX-API-DMAC7.html)
BR122019005883A2 (cg-RX-API-DMAC7.html)
BR112012001263A2 (cg-RX-API-DMAC7.html)
BRPI1004942A2 (cg-RX-API-DMAC7.html)
BR112012000159A2 (cg-RX-API-DMAC7.html)
BR112012007654A2 (cg-RX-API-DMAC7.html)
BR112012005951A2 (cg-RX-API-DMAC7.html)
BR112012000255A2 (cg-RX-API-DMAC7.html)
BR112012000156A2 (cg-RX-API-DMAC7.html)
BR112012007671A2 (cg-RX-API-DMAC7.html)
BRPI0924617A2 (cg-RX-API-DMAC7.html)
BR122017013721A2 (cg-RX-API-DMAC7.html)
JP2012511031A5 (cg-RX-API-DMAC7.html)
BR112012000689A2 (cg-RX-API-DMAC7.html)
BR112012003654A2 (cg-RX-API-DMAC7.html)